The FDA has now started a review of the highly anticipated drug, and AZ is using a priority review voucher to shorten the ...

The FDA has granted accelerated approval to Otsuka’s Voyxact for adults with primary IgAN at risk of disease progression, ...

Lexicon Pharmaceuticals, Inc. currently offers three late-stage assets Zynquista, Inpefa & Pilavapadin. Learn more about LXRX ...

Get the latest on Vera Therapeutics, Inc., FDA progress for atacicept, and IgA nephropathy drug competition. Click to what to ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors had a lower risk for rheumatic disease ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...

A review article discussed the expanding role of biologics in treating components of metabolic syndrome, including glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes and obesity and ...

The US FDA is advancing the drug approval process for sibeprenlimab, a novel targeted drug to help manage immunoglobulin A nephropathy (IgAN).

Voyxact, an APRIL inhibitor, receives FDA accelerated approval for adults with primary IgA nephropathy to reduce proteinuria.